Literature DB >> 24649074

An underlying prognosis predictor of hepatocellular carcinoma: Oncoprotein 18.

Shu Gong1, Zhonghua Tao1, Xiaoyan Liu1, Lin Gan1.   

Abstract

Recent studies have reported the association between the expression of oncoprotein 18 (op18) and hepatocellular carcinoma (HCC). However, any underlying mechanistic connection between op18 expression and hepatocarcinogenesis is poorly understood. In the present study, Flag-pcDNA3.1 vector and Flag-pcDNA3.1-op18 plasmid were stably transfected in SMMC7721 cells, respectively. Stable SMMC7721 control and op18 overexpression SMMC7721 cell lines were constructed and identified by western blot analysis. Using a cell counting kit-8 (CCK8), it was shown that cell proliferation was significantly increased in the op18 overexpression SMMC7721 cell group (0.60±0.05), compared with the control group (0.29±0.03) at an absorbance of 450 nm (P<0.01). Flow cytometry was used to analyze cell apoptosis by FITC-Annexin V and propidium iodide (PI) apoptosis assay kit. The results demonstrated that the percentage of apoptotic cells was inhibited to 5.80±0.33% in the op18 overexpression group, compared with 11.79±1.09% in the control group. Using FACS, single cell analysis data showed that op18 overexpression induced cell cycle arrest by inhibiting progression from G2 to M phase. The results suggest that op18 expression is closely associated with SMMC7721 cell proliferation and apoptosis, which appears to be a potential predictor of prognosis in HCC.

Entities:  

Keywords:  apoptosis; hepatocellular carcinoma; oncoprotein 18; proliferation

Year:  2013        PMID: 24649074      PMCID: PMC3916978          DOI: 10.3892/br.2013.197

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  16 in total

1.  Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.

Authors:  M Long; G Yin; L Liu; F Lin; X Wang; J Ren; J Wei; K Dong; H Zhang
Journal:  Cancer Gene Ther       Date:  2012-01-27       Impact factor: 5.987

Review 2.  Pathways and targets in hepatocellular carcinoma.

Authors:  Amanda Psyrri; Nikolaos Arkadopoulos; Maria Vassilakopoulou; Vassilios Smyrniotis; George Dimitriadis
Journal:  Expert Rev Anticancer Ther       Date:  2012-10       Impact factor: 4.512

Review 3.  Biomarker studies on radiotherapy to hepatocellular carcinoma.

Authors:  Chiao-Ling Tsai; Albert C Koong; Feng-Ming Hsu; Madeline Graber; I-Sin Chen; Jason Chia-Hsien Cheng
Journal:  Oncology       Date:  2013-02-20       Impact factor: 2.935

4.  Novel role of stathmin in microtubule-dependent control of endothelial permeability.

Authors:  Xinyong Tian; Yufeng Tian; Nicolene Sarich; Tinghuai Wu; Anna A Birukova
Journal:  FASEB J       Date:  2012-06-14       Impact factor: 5.191

5.  Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma.

Authors:  Sen-Yung Hsieh; Shiu-Feng Huang; Ming-Chin Yu; Ta-Sen Yeh; Tse-Chin Chen; Yu-Jr Lin; Chee-Jen Chang; Chang-Mung Sung; Yun-Lin Lee; Chih-Yun Hsu
Journal:  Mol Carcinog       Date:  2010-05       Impact factor: 4.784

6.  Up-regulated expression of stathmin may be associated with hepatocarcinogenesis.

Authors:  Lin Gan; Kun Guo; Yan Li; Xiaonan Kang; Lu Sun; Hong Shu; Yinkun Liu
Journal:  Oncol Rep       Date:  2010-04       Impact factor: 3.906

7.  Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer.

Authors:  John Nemunaitis
Journal:  Expert Opin Ther Targets       Date:  2012-06-12       Impact factor: 6.902

Review 8.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

9.  The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.

Authors:  Yi-Ling Chen; Yih-Huei Uen; Chien-Feng Li; Kuo-Chan Horng; Lih-Ren Chen; Wen-Ren Wu; Hong-Yu Tseng; Hsuan-Ying Huang; Li-Ching Wu; Yow-Ling Shiue
Journal:  Ann Surg Oncol       Date:  2012-08-22       Impact factor: 5.344

10.  Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis.

Authors:  Stephan Singer; Volker Ehemann; Antje Brauckhoff; Martina Keith; Sebastian Vreden; Peter Schirmacher; Kai Breuhahn
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

View more
  1 in total

1.  ADNP prompts the cisplatin-resistance of bladder cancer via TGF-β-mediated epithelial-mesenchymal transition (EMT) pathway.

Authors:  Yu Xie; Shuai Zhu; Jinglei Zang; Guanlin Wu; Yuheng Wen; Yu Liang; Ying Long; Weiming Guo; Chuanbing Zang; Xiang Hu; Gang Fan; Shuanglin Xiang; Jian Zhang
Journal:  J Cancer       Date:  2021-06-22       Impact factor: 4.207

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.